This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Contact us

If you would like to make an appointment to connect with a Pfizer representative in a virtual environment and receive information about the medicines promoted by Pfizer whilst retaining the personal touch of a face to face meeting, please fill out the form below. We aim to respond within 5 working days.

Tick which box(es) you would like to receive more information on*

Submit

By clicking 'Submit', you agree that your personal information will be held on a database (located within or outside EU) controlled by Pfizer Limited and used for the purposes agreed to above. Only Pfizer, organisations working with Pfizer in the administration of your information, and Pfizer group companies will have access to your information. We will always employ appropriate technical security measures to protect your personal information and to ensure that it is not accessed by unauthorised persons. You will at any time have the right to access your information, you can request that your information on the Pfizer database is amended, or you can unsubscribe from any programme at any time by emailing us at: [email protected]. To find out more about how Pfizer processes your personal data, including public disclosures of the transfers of value that you may receive from Pfizer, please refer to the Pfizer HCP Privacy Notice at https://privacycenter.pfizer.com/en/hcp.

For general enquiries or information about Pfizer medicines, you can contact Pfizer on 01304 616161

Thank you!

Your form has been submitted. A member of our team will be in contact shortly regarding your enquiry.

PP-SOM-GBR-0954. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No